ER–/PR+ subset of invasive breast carcinoma (IBC): a distinct phenotype with good prognosis

Stolnicu, Simona; Bauer, Orsolya; Naznean, Adrian; Podoleanu, Cristian; Georgescu, Rareş

doi:10.5114/pjp.2018.79551

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, it was not detected expression of ER-/ PRphenotype in non-invasive ductal tumors. In a study conducted by Stolnicu S et al on 112 breast cancer patients, 75% of the samples in that study were positive for ER + / PR + receptors [21).In the present study, 47 (63.5%) of non-invasive and invasive ductal carcinoma specimens had positive ER + / PR + phenotype.The present study is largely consistent with the above study regarding the expression of these positive hormone receptor phenotypes in breast cancer. In a study conducted by Zhang L et al, there was a direct link between expression of ER + / PR + receptors and the response to chemotherapy in breast cancer patients, so careful evaluation of these markers is essential in the therapeutic process [22].…”

Section: Relationship Between Premenopausal and Menopausal Age With Different Er / Pr Expression Phenotypessupporting

confidence: 55%

Histopathologic Characteristics of Invasive and Non-invasive Ductal Tumors have Relationship with Different Phenotypes of ER / PR Receptors in Breast Cancer Patients

Golmohammadi

Mohajeri

Jarrahi

et al. 2021

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

Objective: Contradictory reports have been published regarding the expression levels of the hormone receptors of estrogen and progesterone (ER / PR) and theirclinical importance in diagnosis of breast cancer. The aim of this study was to evaluate the relationship between pathological features of invasive and non-invasive ductal tumors by different ER / PR phenotypes. Methods: This descriptive-analytical study was performed on 74 specimens of breast cancer referred to Isfahan Hospitals for diagnosis between 2015 - 2018. After fixation of the specimens in formalin, tissue passage, cross section and H / E staining, the specimens were divided into two groups: non- invasive and Invasive ductal Carcinoma. After removing of mask, expression of different ER / PR phenotypes was performed using primary monoclonal antibody and immunohistochemically methods. Results: From 74 malignant specimens, 61 (82.4%) were in the category of invasive ductal tumors and 13 cases (17.6%) were in the category of non-invasive ductal tumors. Out of 73 patients with positive ER or PR phenotype 47 samples (63.5%) had ER + / PR +phenotypes, 6 samples had (8.1%) ER+ / PR –phenotype, 20 samples (27%) had ER- / PR + phenotype and only one sample (1.4%) had the ER- / PR- phenotype and was in the category of invasive ductal tumors. There was not detected ER- / PR- phenotype expression in non-invasive ductal tumor. Further analysis showed that there were not significant difference between ER / PR phenotype and tumor stage (p =0.36) or with tumor Grade (P=0.38), high age of menopause or post menopause (P> 0.05). Conclusion: Our data shows that expression of ER- / PR- phenotype only was detected in invasive ductal tumor. It is thought that the tumor type maybe affects the expression of different types of ER / PR hormone receptor phenotypes in breast cancer patients.

show abstract

Section: Relationship Between Premenopausal and Menopausal Age With Different Er / Pr Expression Phenotypessupporting

confidence: 55%

Histopathologic Characteristics of Invasive and Non-invasive Ductal Tumors have Relationship with Different Phenotypes of ER / PR Receptors in Breast Cancer Patients

Golmohammadi

Mohajeri

Jarrahi

et al. 2021

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

show abstract

“…In our study, ISLN-metastasized patients with ER-positive or PR-positive diseases were associated with better survival outcomes. Moreover, we found that 86.6% and 97.1% of patients with ER-positive and PR-positive were downstaged, demonstrating that those ER-positive or PR-positive patients tend to be associated with lower stage and have a better prognosis in comparison with ER-negative and PR-negative tumors 18 - 21 . Another study from Lee et al 22 found that the prognosis of stage III patients with hormone receptor (HR)+/HER2- disease was better than those of stage II patients with HR-/HER2- diseases.…”

Section: Discussionmentioning

confidence: 73%

Integration the biologic factors into the staging of breast cancer patients with ipsilateral supraclavicular lymph node metastasis

et al. 2020

View full text Add to dashboard Cite

Purpose: To investigate the accuracy and the discriminatory performance in the prognostic prediction in breast cancer (BC) patients with ipsilateral supraclavicular lymph node (ISLN) metastasis using the between the American Joint Committee on Cancer (AJCC) 7th and 8th edition staging system. Methods: Female patients diagnosed as BC were retrieved from the Surveillance, Epidemiology, and End Results database between 2010 and 2014. Chi-squared test, Kaplan-Meier method, Cox proportional hazard analysis, and the receiver operating characteristics were used to conduct statistical analysis. Results: We included 1097 BC patients with ISLN metastasis (N3c disease), including 29.4% (n=322) and 70.6% (n=775) of patients with non-metastatic and metastatic stage at diagnosis, respectively. In non-metastatic stage patients, 64.9% of the patients categorized as having stage IIIC disease in the 7th edition AJCC staging system were downstaged to stage IIIA or IIIB according to the 8th AJCC staging criteria. The AJCC 8th edition staging system had better discriminatory prognostic value than the 7th AJCC staging (area under the curve: 0.586 vs. 0.577, P =0.0006), with a 5-year breast cancer-specific survival (BCSS) rate of 71.3%, 62.2%, 45.2% and 39.1% in stage IIIA, IIIB, IIIC, and IV cohorts, respectively ( P <0.0001). The multivariate prognostic analysis revealed that the AJCC 8th edition staging system was an independent prognostic factor for BCSS, while no statistical difference in BCSS was found between the 8th AJCC stage IIIC and IV patients ( P =0.188). Conclusion: The AJCC 8th edition pathological prognostic staging showed a better discriminatory prognostic value in ISLN-metastasized breast cancer patients. An additional clarification strategy in stage IIIC disease based on the 8th AJCC staging should be developed to differentiate patients who are curable with multimodality therapy and patients who have less benefit from curative treatment.

show abstract

“…Currently, ER and PR are known as biomarkers for guiding endocrine therapy and can provide information on prognosis. Compared with ER-negative and PR-negative tumors, those patients with ER-positivity or PR-positivity tend to be associated with lower stage and have a better prognosis ( 23 – 26 ). In our study, patients with ER-positive disease were also associated with better survival outcomes in BC patients with IMN metastasis.…”

Section: Discussionmentioning

confidence: 99%

Staging for Breast Cancer With Internal Mammary Lymph Nodes Metastasis: Utility of Incorporating Biologic Factors

et al. 2021

View full text Add to dashboard Cite

PurposeTo validate the 8th edition of the American Joint Committee on Cancer (AJCC) pathological prognostic staging system for breast cancer patients with internal mammary lymph nodes (IMN) metastasis (N3b disease, stage IIIC in 7th AJCC anatomical staging).MethodsBreast cancer patients with IMN metastasis diagnosed between 2010 and 2014 were retrieved from the Surveillance, Epidemiology, and End Results program. Chi-squared test, Log-rank test, Kaplan-Meier method, and Cox proportional hazard analysis were applied to statistical analysis.ResultsWe included 678 patients with N3b disease in this study. Overall, 68.4% of patients were downstaged to IIIA and IIIB diseases from the 7th anatomical staging to 8th pathological prognostic staging. The new pathological prognostic staging system had better discriminatory value on prognosis prediction among IMN-metastasized breast cancer patients, with a 5-year breast cancer-specific survival (BCSS) of 92.7, 77.4, and 66.0% in stage IIIA, IIIB, and IIIC diseases, respectively (P<0.0001), and the 5-year overall survival (OS) rates was 85.9, 72.1, and 58.7%, respectively (P<0.0001). The results of the multivariate prognostic analysis showed that the new pathological prognostic staging was the independent prognosis related to BCSS and OS, the 8th AJCC pathological prognostic stages showed worse BCSS and OS with gradually increased hazard ratios.ConclusionThe 8th AJCC pathological prognostic staging system offers more refined prognostic stratification to IMN-metastasized breast cancer patients and endorses its use in routine clinical practice for this specific subgroup of breast cancer.

show abstract

ER–/PR+ subset of invasive breast carcinoma (IBC): a distinct phenotype with good prognosis

Cited by 7 publications

References 0 publications

Histopathologic Characteristics of Invasive and Non-invasive Ductal Tumors have Relationship with Different Phenotypes of ER / PR Receptors in Breast Cancer Patients

Histopathologic Characteristics of Invasive and Non-invasive Ductal Tumors have Relationship with Different Phenotypes of ER / PR Receptors in Breast Cancer Patients

Integration the biologic factors into the staging of breast cancer patients with ipsilateral supraclavicular lymph node metastasis

Staging for Breast Cancer With Internal Mammary Lymph Nodes Metastasis: Utility of Incorporating Biologic Factors

Contact Info

Product

Resources

About